Participated · Seed · Oct 2025

Founded in 2022 in Tel Aviv, Israel, Asterix Foods builds plant cell culture systems designed to overcome the high capital costs and scalability bottlenecks of traditional precision fermentation. Its compact, low-CAPEX bioreactors operate at room temperature, cut energy and water use, and can run multiple production lines to manufacture diverse bioactive proteins year-round with minimal downtime. Because the units are modular and resource-light, facilities can be deployed on non-arable land and co-located with manufacturing hubs to reduce logistics costs and emissions. The company currently runs a pilot facility in central Tel Aviv that showcases this flexible approach. A multidisciplinary team of eight Ph.D.-level researchers in biotechnology and engineering leads product development. With fresh capital, Asterix plans to expand the pilot plant and start sending product samples to select customers, moving toward commercial-scale production.

Led · Seed · Mar 2025

Differential Bio emerged from stealth in Munich with a Virtual Scale-up Platform that integrates advanced microbiology, robotics-driven lab automation, and AI to simulate and optimize bioprocesses. The platform miniaturises fermentation, generates high-quality phenotypic and bioprocess data through automated workflows, and applies machine learning to reduce reliance on costly physical experiments. In the probiotics industry the company reported a 4x increase in biomass yield and a 16% reduction in production costs when transitioning a strain to plant-based media. Differential Bio says its approach speeds optimisation cycles, lowers development costs, and improves yields to address biomanufacturing's scaling bottlenecks. The company raised €2 million in a pre-seed round and will use the funds to enhance the Virtual Scale-up Platform, tackle more complex multi-strain systems and novel bio-products, scale its automated "self-driving lab", recruit talent, and onboard new clients.

Participated · Seed · Nov 2024

Ulysses builds underwater autonomous vehicles designed to map and monitor the oceans. The company is Irish co-founded and operates from San Francisco, with founders including Akhil V., Will O'Brien, Colm O'Brien and Jamie Wedderburn. It recently completed combined fundraising totaling $46 million (€39 million) from a seed round and a Series A. The Series A was led by Andreessen Horowitz and the seed by pebblebed. The article does not disclose revenue, user metrics, or a valuation. No specific product roadmap milestones or use-of-funds breakdown were reported.

Participated · Seed · Oct 2024

CREW Carbon offers a process intensification solution for wastewater treatment that uses strategically-sourced alkaline minerals to optimize pH and alkalinity, improving biological performance, settleability, and plant capacity while permanently sequestering CO2. Since beginning commercial operations in 2024, CREW has deployed at nearly 10 facilities across the U.S. and Europe and secured long-term RFPs with utilities. The company has captured over 2,000 tons of CO2 and secured more than $33 million in carbon removal offtake agreements, delivering verified carbon removal credits to corporate buyers. CREW has developed proprietary measurement, reporting, and verification (MRV) capabilities and is developing a scalable analytics platform to provide operational insights and process optimization. Financial and strategic support from the Series A will be used to scale deployments, expand customer engagements, and add key hires in wastewater process, technology, supply chain, and business development.

Participated · Seed · Sep 2024

PACT operates a sustainable biomaterial platform that engineers collagen-based materials designed to serve as an alternative to plastic-derived textiles. The company’s technology focuses on creating fibers and fabrics that match or exceed the performance of petroleum-based synthetics while being biodegradable and more environmentally friendly. According to the article, PACT is now preparing to scale production of its collagen textile solution, directing new capital toward expanding manufacturing capacity and further R&D. Management positions the product as a drop-in replacement for plastic textiles in fashion and other industries seeking to cut plastic use. The Series A financing underscores growing investor interest in next-generation biomaterials that can help decarbonize the supply chain. Although detailed operating metrics were not disclosed, the round signals confidence in PACT’s platform and commercial roadmap.